Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

1. Baloxavir marboxil (Xofluza) - For the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours

Baloxavir marboxil (Xofluza) - For the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours Drug Approval Package: Xofluza Film-Coated Tablets (Baloxavir marboxil) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Xofluza Film-Coated Tablets (Baloxavir marboxil) Company: Shionogi, Inc. Application Number: 210854 Approval Date: 10/24/2018 Persons with disabilities having problems accessing the PDF

FDA - Drug Approval Package2018

2. Influenza infection

Influenza infection Influenza infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Influenza infection Last reviewed: November 2018 Last updated: November 2018 Summary Characterised by upper and lower respiratory tract symptoms of rhinorrhoea, cough, fever, chills, headache, and myalgia. Typically presents in winter season. Can occur in local community outbreaks, epidemics, and, rarely, pandemics. Vaccination (...) for prevention is available. Definition Acute respiratory tract infection typically caused by seasonal influenza A or B virus. The virus is transmitted by inhalation of infected respiratory secretions that have been aerosolised through coughing, sneezing, or talking. Brankston G, Gitterman L, Hirji Z, et al. Transmission of influenza A in human beings. Lancet Infect Dis. 2007;7:257-265. http://www.ncbi.nlm.nih.gov/pubmed/17376383?tool=bestpractice.com History and exam winter season current influenza outbreak

BMJ Best Practice2018

3. Update: Can Newer Rapid Influenza Tests Rule Out Disease?

Update: Can Newer Rapid Influenza Tests Rule Out Disease? Annals of Emergency Medicine Email/Username: Password: Remember me Search Terms Search within Search Share this page Copyright © 2018 Inc. All rights reserved. | | | | | | The content on this site is intended for health professionals. We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the . Advertisements on this site do not constitute a guarantee or endorsement by the journal

Annals of Emergency Medicine Systematic Review Snapshots2018

4. VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B

VAXELIS, hexavalent vaccine against diphtheria, tetanus, poliomyelitis, pertussis, Haemophilus influenzae type b infections, hepatitis B Haute Autorité de Santé - VAXELIS, vaccin hexavalent contre diphtérie, tétanos, poliomyélite, coqueluche, infections à Haemophilus influenzae type b, hépatite B Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les (...) Médicaments VAXELIS, vaccin hexavalent contre diphtérie, tétanos, poliomyélite, coqueluche, infections à Haemophilus influenzae type b, hépatite B Substance active (DCI) vaccin diphtérique, tétanique, coquelucheux (acellulaire, multicomposé), de l'hépatite B (ADNr), poliomyélitique (inactivé) et conjugué de l'Haemophilus de type b (adsorbé) INFECTIOLOGIE - Nouveau médicament Nature de la demande Inscription Avis de la CT du 11 octobre 2017 Pas d’avantage clinique démontré pour la primovaccination et le

Haute Autorite de sante2018

5. VAXIGRIPTETRA, tetravalent vaccine against seasonal influenza

VAXIGRIPTETRA, tetravalent vaccine against seasonal influenza Haute Autorité de Santé - VAXIGRIPTETRA, vaccin quadrivalent contre la grippe saisonnière Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments VAXIGRIPTETRA, vaccin quadrivalent contre la grippe saisonnière Substance active (DCI) vaccin grippal quadrivalent, inactivé, à virion (...) fragmenté INFECTIOLOGIE - Nouveau médicament Nature de la demande Inscription Avis de la CT du 27 septembre 2017 Pas d’avantage clinique démontré par rapport aux vaccins trivalents inactivés VAXIGRIPTETRA est un vaccin injectable, inactivé à virion fragmenté, qui a l’AMM dans l'immunisation active des adultes et des enfants à partir de 3 ans pour la prévention de la grippe causée par les deux sous-types viraux de la grippe A et les deux types viraux de la grippe B contenus dans le vaccin. Il se

Haute Autorite de sante2018

6. INFLUVAC TETRA, tetravalent vaccine against seasonal influenza

INFLUVAC TETRA, tetravalent vaccine against seasonal influenza Haute Autorité de Santé - INFLUVAC TETRA, vaccin tétravalent contre la grippe saisonnière Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments INFLUVAC TETRA, vaccin tétravalent contre la grippe saisonnière Substance active (DCI) vaccin grippal quadrivalent, inactivé, à antigènes de (...) surface INFECTIOLOGIE - Nouveau médicament Nature de la demande Inscription Avis de la CT du 22 novembre 2017 Intérêt clinique important en prévention de la grippe mais pas d’avantage clinique par rapport aux vaccins trivalents inactivés INFLUVAC TETRA est un vaccin injectable qui a l’AMM dans l'immunisation active pour la prévention de la grippe causée par les deux sous-types viraux de la grippe A et les deux types viraux de la grippe B contenus dans le vaccin. Il se distingue des vaccins grippaux

Haute Autorite de sante2018

7. The use of antiviral drugs for influenza: Guidance for practitioners

The use of antiviral drugs for influenza: Guidance for practitioners This practice point summarizes the use of antiviral drugs to manage influenza illness in children and youth. Recommendations are based on previously published Canadian recommendations for clinicians on the use of antiviral drugs to prevent and treat influenza. Detailed information on the selective use of chemoprophylaxis can be found in the original document, which also highlights the importance of secondary bacterial (...) infections (i.e., Streptococcus pneumoniae , methicillin-sensitive  Staphylococcus aureus and methicillin-resistant  S. aureus ) in cases of severe influenza illness. This document serves as a reference for all clinicians while providing general principles and a user-friendly flow diagram to assist decision-making. Keywords : Antiviral therapy; Children; Influenza; Neuraminidase inhibitors

Canadian Paediatric Society2018

8. Vaccine recommendations for children and youth for the 2018/2019 influenza season

Vaccine recommendations for children and youth for the 2018/2019 influenza season The Canadian Paediatric Society continues to encourage annual influenza vaccination for ALL children and youth ≥6 months of age. Recommendations from the National Advisory Committee on Immunization (NACI) for the 2018/2019 influenza season are not substantially changed from those of last season. Quadrivalent vaccine, if available, is recommended for children 6 months to 17 years of age. Either inactivated (...) influenza vaccine or live attenuated influenza vaccine may be used for children and youth 2 to 17 years of age who are not immunocompromised. Keywords:   Children; Influenza vaccine; Inactivated influenza vaccine; LAIV; NACI

Canadian Paediatric Society2018

9. Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza

Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza - ACOG Menu ▼ Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza Page Navigation ▼ Number 753, October 2018 Immunization, Infectious Disease, and Public Health Preparedness Expert Work Group The Society for Maternal-Fetal Medicine endorses this document. This Committee Opinion was developed by the American (...) with other organizations, conflict of interest disclosures by representatives of the other organizations are addressed by those organizations. The American College of Obstetricians and Gynecologists has neither solicited nor accepted any commercial involvement in the development of the content of this published product. Assessment and Treatment of Pregnant Women With Suspected or Confirmed Influenza ABSTRACT: Pregnant and postpartum women are at high risk of serious complications of seasonal and pandemic

American College of Obstetricians and Gynecologists2018

10. Avian influenza A (H5N1) virus infection

Avian influenza A (H5N1) virus infection Avian influenza A (H5N1) virus infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Avian influenza A (H5N1) virus infection Last reviewed: August 2018 Last updated: September 2018 Summary Notifiable condition. Infection control measures, such as standard, droplet, contact, and airborne precautions, are recommended. High case-fatality rate of approximately 53% among (...) . Definition A contagious disease of animals caused by viruses that infect birds and, less commonly, pigs. Avian influenza A viruses are highly species-specific but have infected other mammals and, on rare occasions, have crossed the species barrier to infect humans. Highly pathogenic avian influenza (HPAI) A H5N1 virus originating in poultry and wild birds can be transmitted to humans, with rare cases of infection transmitted between humans. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person

BMJ Best Practice2018

11. Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents.

Baloxavir Marboxil for Uncomplicated Influenza in Adults and Adolescents. BACKGROUND: Baloxavir marboxil is a selective inhibitor of influenza cap-dependent endonuclease. It has shown therapeutic activity in preclinical models of influenza A and B virus infections, including strains resistant to current antiviral agents. METHODS: We conducted two randomized, double-blind, controlled trials involving otherwise healthy outpatients with acute uncomplicated influenza. After a dose-ranging (10 to 40 (...) mg) placebo-controlled trial, we undertook a placebo- and oseltamivir-controlled trial of single, weight-based doses of baloxavir (40 or 80 mg) in patients 12 to 64 years of age during the 2016-2017 season. The dose of oseltamivir was 75 mg twice daily for 5 days. The primary efficacy end point was the time to alleviation of influenza symptoms in the intention-to-treat infected population. RESULTS: In the phase 2 trial, the median time to alleviation of influenza symptoms was 23.4 to 28.2 hours

NEJM2018

12. Prevalence of seasonal influenza vaccination among primary healthcare workers in Arar city, Saudi Arabia

Prevalence of seasonal influenza vaccination among primary healthcare workers in Arar city, Saudi Arabia 30214704 2018 11 14 2008-5842 10 8 2018 Aug Electronic physician Electron Physician Prevalence of seasonal influenza vaccination among primary healthcare workers in Arar city, Saudi Arabia. 7217-7223 10.19082/7217 Influenza outbreaks occur annually and have significant ramifications on the wellbeing of the population. Influenza is given high priority in Saudi Arabia where numerous reports (...) of different types of influenza outbreaks have occurred in recent years. The study aimed to determine the prevalence of influenza vaccination among healthcare providers. The study employed a cross-sectional design, and data was collected using a predesigned questionnaire which was validated by a panel of experts and tested for reliability (Cronbach's alpha =0.8). All primary healthcare workers in Arar city (Saudi Arabia) were taken as a comprehensive sample between January and March 2018. The questionnaire

Electronic physician2018 Full Text: Link to full Text with Trip Pro

13. Conjugate Haemophilus influenzae type b vaccines for sickle cell disease.

Conjugate Haemophilus influenzae type b vaccines for sickle cell disease. BACKGROUND: People affected with sickle cell disease (SCD) are at high risk of infection from Haemophilus influenzae type b (Hib). Before the implementation of Haemophilus influenzae type b conjugate vaccination in high-income countries, this was responsible for a high mortality rate in children under five years of age. In African countries, where coverage of this vaccination is still extremely low, Hib remains one (...) of the most common causes of bacteraemias in children with SCD. The increased uptake of this conjugate vaccination may substantially improve the survival of children with SCD. This is an update of a previously published Cochrane Review. OBJECTIVES: The primary objective was to determine whether Hib conjugate vaccines reduce mortality and morbidity in children and adults with SCD.The secondary objectives were to assess the following in children and adults with SCD: the immunogenicity of Hib conjugate

Cochrane2018

14. Influenza

Influenza Top results for influenza - Trip Database or use your Google+ account Liberating the literature My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing (...) the search button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for influenza The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines

Trip Latest and Greatest2018

15. Influenza vaccine for chronic obstructive pulmonary disease (COPD).

Influenza vaccine for chronic obstructive pulmonary disease (COPD). BACKGROUND: Influenza vaccinations are currently recommended in the care of people with COPD, but these recommendations are based largely on evidence from observational studies, with very few randomised controlled trials (RCTs) reported. Influenza infection causes excess morbidity and mortality in people with COPD, but there is also the potential for influenza vaccination to cause adverse effects, or not to be cost effective (...) . OBJECTIVES: To determine whether influenza vaccination in people with COPD reduces respiratory illness, reduces mortality, is associated with excess adverse events, and is cost effective. SEARCH METHODS: We searched the Cochrane Airways Trials Register, two clinical trials registries, and reference lists of articles. A number of drug companies we contacted also provided references. The latest search was carried out in December 2017. SELECTION CRITERIA: RCTs that compared live or inactivated virus

Cochrane2018

16. Peramivir (Alpivab) - Influenza, Human

Peramivir (Alpivab) - Influenza, Human 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. 22 February 2018 EMA/CHMP/148367/2018 Committee for Medicinal Products for Human Use (CHMP) Assessment report Alpivab International non (...) Limited submitted on 22 December 2016 an application for marketing authorisation to the European Medicines Agency (EMA) for Alpivab, through the centralised procedure falling within the Article 3(1) and point 3 of Annex of Regulation (EC) No 726/2004. The eligibility to the centralised procedure was agreed upon by the EMA/CHMP on 24 September 2015. The applicant applied for the following indication: Treatment of influenza Alpivab is indicated in adults 18 years and older with symptoms typical

European Medicines Agency - EPARs2018

17. Influenza Vaccination During Pregnancy

Influenza Vaccination During Pregnancy VOL. 131, NO. 4, APRIL 2018 OBSTETRICS & GYNECOLOGY e109 Influenza Vaccination During Pregnancy ABSTRACT: Influenza vaccination is an essential element of prepregnancy, prenatal, and postpartum care because influenza can result in serious illness, including a higher chance of progressing to pneumonia, when it occurs during the antepartum or postpartum period. In addition to hospitalization, pregnant women with influenza are at increased risk of intensive (...) care unit admission and adverse perinatal and neonatal outcomes. The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices and the American College of Obstetricians and Gynecologists recommend that all adults receive an annual influenza vaccine and that women who are or will be pregnant during influenza season receive an inactivated influenza vaccine as soon as it is available. In the United States, the influenza season typically occurs from October to May. Ideally

American College of Obstetricians and Gynecologists2018

18. Interventions to increase influenza vaccination rates of those 60 years and older in the community.

Interventions to increase influenza vaccination rates of those 60 years and older in the community. BACKGROUND: The effectiveness of interventions to increase influenza vaccination uptake in people aged 60 years and older varies by country and participant characteristics. This review updates versions published in 2010 and 2014. OBJECTIVES: To assess access, provider, system, and societal interventions to increase the uptake of influenza vaccination in people aged 60 years and older (...) in the community. SEARCH METHODS: We searched CENTRAL, which includes the Cochrane Acute Respiratory Infections Group's Specialised Register, MEDLINE, Embase, CINAHL, and ERIC for this update, as well as WHO ICTRP and ClinicalTrials.gov for ongoing studies to 7 December 2017. We also searched the reference lists of included studies. SELECTION CRITERIA: Randomised controlled trials (RCTs) and cluster-randomised trials of interventions to increase influenza vaccination in people aged 60 years or older

Cochrane2018

19. A trial like ALIC4E: why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness?

A trial like ALIC4E: why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness? 29761108 2018 11 14 2312-0541 4 2 2018 Apr ERJ open research ERJ Open Res A trial like ALIC 4 E: why design a platform, response-adaptive, open, randomised controlled trial of antivirals for influenza-like illness? 00046-2018 10.1183/23120541.00046-2018 ALIC 4 E is the first publicly funded, multicountry, pragmatic study determining whether antivirals should (...) be routinely prescribed for influenza-like illness in primary care. The trial aims to go beyond determining the average treatment effect in a population to determining effects in patients with combinations of participant characteristics (age, symptom duration, illness severity, and comorbidities). It is one of the first platform, response-adaptive, open trial designs implemented in primary care, and this article aims to provide an accessible description of key aspects of the study design. 1) The platform

ERJ open research2018 Full Text: Link to full Text with Trip Pro

20. Epilepsy in Children After Pandemic Influenza Vaccination

Epilepsy in Children After Pandemic Influenza Vaccination 29449342 2018 02 16 1098-4275 2018 Feb 15 Pediatrics Pediatrics Epilepsy in Children After Pandemic Influenza Vaccination. e20170752 10.1542/peds.2017-0752 To determine if pandemic influenza vaccination was associated with an increased risk of epilepsy in children. Information from Norwegian registries from 2006 through 2014 on all children <18 years living in Norway on October 1, 2009 was used in Cox regression models to estimate hazard (...) ratios for incident epilepsy after vaccination. A self-controlled case series analysis was used to estimate incidence rate ratios in defined risk periods after pandemic vaccination. In Norway, the main period of the influenza A subtype H1N1 pandemic was from October 2009 to December 2009. On October 1, 2009, 1 154 113 children <18 years of age were registered as residents in Norway. Of these, 572 875 (50.7%) were vaccinated against pandemic influenza. From October 2009 through 2014 there were 3628

EvidenceUpdates2018